Fraud Investigation Launched Against Oculis Holding AG

What happened

The Schall Law Firm has announced an investigation into Oculis Holding AG for potential securities fraud, sending shares lower. The investigation adds legal overhang to a stock already trading near the high end of our fair value estimate. Oculis is a pre-revenue biotech awaiting pivotal Phase 3 DIAMOND DME data in Q2 2026, with a market cap of ~$1.2B. Our base case values the company at $26, while the bear case of $12 reflects trial failure or regulatory setbacks. The fraud probe introduces additional downside risk that the current price does not adequately discount.

Implication

While the investigation's ultimate impact is uncertain, it increases the asymmetry of risk/reward for Oculis. The stock already priced in significant optimism for OCS-01 success; this overhang could weigh on the stock irrespective of clinical data. Long-term investors should demand a wider margin of safety, with an attractive entry near our $15 floor, and monitor for any substantive allegations that could impair the company's ability to raise capital or partner.

Thesis delta

The fraud investigation introduces a new binary risk beyond clinical and regulatory outcomes. Our bear case probability increases from 35% to 40-45% as legal costs and reputation damage could distract management and delay milestones. The stock's risk/reward skews more negative until the investigation's scope is clarified or dismissed.